

Freedom of Information Act 2000 – Request Reference FoI/24/360
Migraine Treatment

A. How many patients have been treated with the following drugs in the past 4 months:

For the period 1 February 2024 to 31 May 2024, the below drugs were issued as follows.

- Atogepant (Aquipta) – any disease – 0
- Erenumab (Aimovig) – any disease – 37
- Eptinezumab (Vyepiti) – any disease – 9
- Fremanezumab (Ajovy) – any disease – 3
- Galcanezumab (Emgality) – any disease – 15
- Rimegepant (Vydura) – any disease – 0
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) – any disease – 93

Cardiff and Vale University Health Board is unable to provide information on the number of drugs issued for specific diseases without exceeding the appropriate limit of 18 hours pursuant to the Appropriate Limit and Fees Regulations 2004. The response for 'Botulinum Toxin' therefore reflects issues for any disease, and not only migraines.

B. We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality, Vyepiti, Vydura & Aquipta) for migraine. Could you please answer the following:

- **Does the trust commission/fund Botox treatment for migraine (Y/N)?**

Yes.

- **Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?**

Yes.

- **Does the trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust (Y/N)? In case the trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments?**

Yes.

- **In case the trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.**

Not applicable.